Upstream Processing

The companies partnered to build a 500-L single-use pilot-scale plant for biologics production.

The maturation of single-use technologies presents commercial bioprocessing options for small-volume drug products.

The provider of plant-based ingredients will present recently launched multi-compendial materials for upstream and downstream biopharmaceutical applications.

New products were developed as next-generation process intensification technologies, MilliporeSigma reports.

Sharing of bioprocessing know-how can help resolve pressing industry problems.

Trace elements in raw materials may impact the quality and safety of the finished biologic product, according to industry experts.

Biopharma seeks alternatives that meet the needs for next-gen biologic drug production.

The quality of the cell lines used to manufacture biopharmaceuticals are crucial for the production of high-quality, stable biopharmaceuticals.

Biopharma companies can balance competing demands from patients, investors, and regulators by keeping a focus on science.

Late-stage and commercial biomanufacturing pose a challenge to cell-culture processing.

Understanding differences in bioreactor lifecycle, design space, and product platforms is important for selecting a bioreactor type.

This article discusses affinity capture for tier determination and surveys a broad collection of commonly and less commonly used assays to analyze cell culture media

Transcriptomics plays a role in influencing the production of recombinant therapeutics in microbial and mammalian hosts.

The need to improve and understand processes is moving PAT and more advanced control strategies beyond the lab into manufacturing and downstream applications.

More published data and initial regulatory approvals are needed to drive adoption of continuous bio-manufacturing.

The new platform is expected to speed up cell line development.

Fujifilm acquires cell culture media companies Irvine Scientific Sales Company and IS Japan.

Developments and investments in single-use systems advance upstream biomanufacturing.

Sartorius Stedim Biotech has launched a new automated parallel bioreactor system for perfusion culture.

The contract development and manufacturing organization has expanded biologics capacity at its facility in Berkeley, CA.

Under this agreement, the companies will develop in parallel an antibody drug candidate and cell lines for other potential candidates.

Modeling at various stages of the data analytics continuum aids scale comparison of a bioreactor.

The study suggests that circumventing evolution in cell factories can enable the commercialization of new biobased chemicals to large-scale.

Corning will feature its 3D bioprinting technology and tools to support 3D cell culture at booth #1029 during the SLAS 2018 conference on Feb. 3-7, 2018 in San Diego, CA.

Comecar will provide cell culture equipment for biopharmaceutical company CO.DON AG's new production site in Leipzig, Germany.

Recent investments show expansion activity in cell culture facilities.

MilliporeSigma will collaborate with IPS and G-CON to offer end-to-end, turnkey, modular MAb manufacturing.

BioTek Instruments has released a second edition of its BioSpa software that now offers users a simplified but effective interface for kinetic imaging or detection workflows.

Gilead Sciences will acquire Cell Design Labs to further cell-therapy research and development efforts.

A quality-by-design approach that implements PAT offers advantages in upstream cell-culture processing.